Expense

BILL Unveils New Features for BILL Spend & Expense to Enhance Visibility and Control of Business Finances for SMBs and Accountants

Retrieved on: 
Wednesday, December 13, 2023
Software, Data Analytics, Finance, Small Business, Accounting, Professional Services, Technology, Business, Spend, Human, State Finance Accountability Committee, NYSE, Policy, Multimedia, Trust, Luigi, Data analysis, Divvy, Travel, Construction, Expense, Growth, BILL

View the full release here: https://www.businesswire.com/news/home/20231213541015/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231213541015/en/
    “For SMBs, correctly managing spend can be the difference between success and failure.
  • The BILL Spend & Expense budgets interface has been reimagined, focusing on making budget management even more intuitive for spenders and admins.
  • “BILL Spend & Expense gives us the tools our clients need to create better visibility, controls, and workflows.
  • Watch this video to learn more about how BILL Spend & Expense can help with visibility and control of business finances.

Airbase Expands Global Expense Management with AI Innovation

Retrieved on: 
Tuesday, November 14, 2023
Technology, Payments, Finance, Fintech, Accounting, Professional Services, Software, Internet, Artificial Intelligence, Organization, Expense, Comptroller, Expense management, Machine learning, TravelPerk, OCR, IDC, Environment, Travel, Sales, Air base

Airbase expense management frees employees and accounting teams from the time-consuming drudgery of manually submitting expense reports and processing reimbursements.

Key Points: 
  • Airbase expense management frees employees and accounting teams from the time-consuming drudgery of manually submitting expense reports and processing reimbursements.
  • For businesses that support global operations and remote workers, Airbase expense management helps ensure compliance and faster reimbursements to employee bank accounts globally.
  • “To solve the complex problems of global payments and expense compliance, we rely on the most advanced and trusted technologies.
  • Airbase AI-driven expense management experience: Airbase uses generative AI and machine learning to automatically extract the details of each receipt, including generating the expense reason and details in the memo field.

Altus Power, Inc. Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Environment, Commercial Building & Real Estate, Technology, Construction & Property, Utilities, Alternative Energy, Software, Green Technology, Energy, Disposal, EBITDA, Accounting, Acquisition, NYSE, Equipment, Earnout, Depreciation, Bank statement, Annual report, Expense, Samsung Galaxy Note 20, PAR, Multimedia, Alignment, Interest expense, FASB, REC, GAAP, Professional, CBRE, Gain, Retirement, Redmi Note 11, Mergers and acquisitions, Growth, Entity, Accretion expense, PPA, NMCA, Renewable energy, Asset management, Bank, Insurance, Bookkeeping, Security (finance)

Altus Power, Inc. (NYSE: AMPS), the leading commercial-scale provider of clean electric power, today announced its financial results for the third quarter of 2023.

Key Points: 
  • Altus Power, Inc. (NYSE: AMPS), the leading commercial-scale provider of clean electric power, today announced its financial results for the third quarter of 2023.
  • Third quarter 2023 GAAP net income totaled $6.8 million, compared to net loss of $96.6 million for the same period last year.
  • Adjusted EBITDA* during the third quarter of 2023 was $29.1 million, compared to $19.4 million for the third quarter of 2022, a 50% increase.
  • Altus Power reaffirmed 2023 adjusted EBITDA* in the range of $97-103 million, representing approximately 70% growth over 2022.

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Stem Cells, Biotechnology, Pharmaceutical, Optical, Oncology, Health, Health Technology, Clinical Trials, Webcast, RPE, Interest, B2M, Research, VAC, D, Therapy, Visual acuity, OCT, IND, Lineage Cell Therapeutics, Eterna, INL, Patient, FDA, Collaboration, G&A, OPL, Expense, Investigational New Drug, NYSE American, Trial of the century, ELM, AMD, Geographic atrophy, Roche, Survival, Partnership, Congress, Letter, TASE, NK, Pharmaceutical industry, Fine chemical, Vaccine, Genentech

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

Emmaus Life Sciences Reports Q3 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
OTCQX, Expense, Sickle cell disease, Cryptocurrency, Reinsurance, Glutamine, MENA

TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.

Key Points: 
  • TORRANCE, Calif., Nov. 14, 2023 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2023.
  • Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for same periods in 2022.
  • Total operating expenses for the nine months ended September 30, 2023 were $19.2 million, compared with $15.7 million for the same period in 2022.
  • At September 30, 2023, the company had cash and cash equivalents of $1.5 million, compared with $2.0 million on December 31, 2022.

LiqTech International Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Sale, Water, Swimming, MEG, DPF, Growth, Expense, Aqua, Hand, O&G, Rare-earth element, Video game, Cryptocurrency, Fishing, Renewable energy, List of islands in the Pacific Ocean

BALLERUP, Denmark, Nov. 9, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023.

Key Points: 
  • BALLERUP, Denmark, Nov. 9, 2023 /PRNewswire/ -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the third quarter of 2023 for the period ended September 30, 2023.
  • Revenue for the quarter ended September 30, 2023, was $5.1 million, compared to the $3.3 million reported in the third quarter of 2022.
  • Cash on hand (including restricted cash) on September 30, 2023 was $11.8 million compared to $12.6 million on June 30, 2023.
  • Replay: A teleconference replay of the call will be available until November 16, 2023, at (877) 344-7529 or (412) 317-0088, confirmation # 8554685.

CNH Industrial N.V. Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023
Adjustment, CNH Industrial, United Kingdom, Financial services, Industrial, CNH, GAAP, FX, EBIT, Bank statement, Nature, Expense, EPS, Uncertainty, European Free Trade Association, Net, Table, Investment, Collection, European, EU, ERP, Continental, Bank, Risk management, Renting

CNH Industrial reports quarterly and annual consolidated financial results under U.S. GAAP and EU-IFRS.

Key Points: 
  • CNH Industrial reports quarterly and annual consolidated financial results under U.S. GAAP and EU-IFRS.
  • CNH Industrial monitors its operations through the use of several non-GAAP financial measures.
  • CNH Industrial’s management believes that these non-GAAP financial measures provide useful and relevant information regarding its operating results and enhance the readers’ ability to assess CNH Industrial’s financial performance and financial position.
  • Adjusted EBIT Margin of Industrial Activities: is computed by dividing Adjusted EBIT of Industrial Activities by Net Sales of Industrial Activities.

Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, November 3, 2023
FDA, Research, Sale, National Institute of Allergy and Infectious Diseases, AstraZeneca, Ventilator-associated pneumonia, Antibiotic, Cystic Fibrosis Foundation, VAP, Omicron, NIAID, European Medicines Agency, OTCQB, Tenant, Development, Pharmacokinetics, Priority review, Data monitoring committee, Common stock, QIDP, Pseudomonas aeruginosa, Expense, Nature Communications, COVID-19, Cystic fibrosis, S. aureus, Emory University, EMA, Staphylococcus, Gallium, NIH, Safety, Infection, Patient, Administration, Mab, BLA, Bangladesh Technical Education Board, Respiratory tract, DSMB, ICU, Pharmaceutical industry, Vaccine, Security (finance)

LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Key Points: 
  • OTCQB companies must be current in their financial reporting and undergo an annual verification and management certification process.
  • We remain optimistic of successful outcomes from these efforts in the coming months,” commented Vu Truong, Ph.D., Chief Executive Officer of Aridis Pharmaceuticals.
  • Due to fair value option valuation of our notes payable, there was no interest expense recorded during the third quarter of 2023.
  • Other Income: Other income increased to $26,000 for the quarter ended September 30, 2023, compared to approximately $23,000 for the quarter ended September 30, 2022.

Kontoor Brands Reports 2023 Third Quarter Results; Updates 2023 Outlook

Retrieved on: 
Thursday, November 2, 2023
Fashion, Online Retail, Retail, Manufacturing, Specialty, Textiles, Ratio, Line of credit, Growth, Wrangler, Brand, Kontoor Brands, NYSE, Notional amount, U.S. Customs and Border Protection, SG, EBITDA, GAAP, United States Customs Service, Interest, Internet, Lee, Expense, EPS, Capital expenditure, Depreciation, KTB, General Administration of Press and Publication, DTC, Investment, Administration, Bank, Bookkeeping, Security (finance), Video game, Arms industry, Pharmaceutical industry, Health insurance, International

And we delivered another solid quarter in DTC, a critical growth pillar of our diversified, accretive growth strategy,” said Scott Baxter, President, Chief Executive Officer and Chair of Kontoor Brands.

Key Points: 
  • And we delivered another solid quarter in DTC, a critical growth pillar of our diversified, accretive growth strategy,” said Scott Baxter, President, Chief Executive Officer and Chair of Kontoor Brands.
  • Late in the third quarter of 2023, management identified inaccuracies in processing certain transactions with U.S. Customs and Border Protection (“U.S.
  • These inaccuracies resulted in underpayment of certain duties owed to U.S. Customs for the 2021 to 2023 periods.
  • Kontoor Brands will host its third quarter conference call beginning at 8:30 a.m. Eastern Time today, November 2, 2023.

Omnicell Announces Third Quarter 2023 Results; Updates Fiscal Year 2023 Guidance and Announces Reduction in Force

Retrieved on: 
Thursday, November 2, 2023
Health Technology, Pharmaceutical, Health, Expense, EBITDA, GAAP, Pharmacy, Hospital, OMCL, Weakness, Safety, Total, Robotics, Cryptocurrency, Video game, Renewable energy, Bank, Omnicell

Total GAAP net income for the third quarter of 2023 was $6 million, or $0.12 per diluted share.

Key Points: 
  • Total GAAP net income for the third quarter of 2023 was $6 million, or $0.12 per diluted share.
  • The Company expects fourth quarter 2023 product revenues to be between $142 million and $152 million, and fourth quarter 2023 service revenues to be between $105 million and $115 million.
  • The Company expects fourth quarter 2023 non-GAAP earnings per share to be between $0.07 and $0.22 per share.
  • The Company’s fourth quarter and full year 2023 guidance has been adjusted to include the anticipated effects and expected impact of current macroeconomic headwinds.